We are live on !
Find out more
Artia Global Partners Portfolio holdings
AUM
$542M
Turnover
28.07%
1-Year Est. Return
206.64%
This Fund
S&P 500
This Quarter Est. Return
+28.45%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$42.4M
(+8.5%)
Cap. Flow
+$30.9M
Cap. Flow % of AUM
Cap. Flow %
5.7%
Top 10 Holdings %
Top 10 Hldgs %
64.55%
Holding
57
New
7
Increased
11
Reduced
3
Closed
9
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.4
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.5
years
Top 20 Avg Time Held Equity only
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BrightSpring Health Services
BTSG
|
+$25.7M |
| 2 |
Alkermes
ALKS
|
+$17.5M |
| 3 |
Travere Therapeutics
TVTX
|
+$11.9M |
| 4 |
Revolution Medicines
RVMD
|
+$8.82M |
| 5 |
Celcuity
CELC
|
+$5.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$35.2M |
| 2 |
Abivax
ABVX
|
+$9.5M |
| 3 |
Terns Pharmaceuticals
TERN
|
+$5.53M |
| 4 |
Insmed
INSM
|
+$4.8M |
| 5 |
AbbVie
ABBV
|
+$3.15M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.08% |
| 2 | Miscellaneous | 2.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Abivax
ABVX
$7.82B
| $68.8M | 12.7% |
516,447
-84,300
| -14% | -$9.5M |
2025 Q3
3 quarters
|
|
|
2
Insmed
INSM
$21.2B
| $62.8M | 11.59% |
589,052
-39,660
| -6% | -$4.8M |
2023 Q4
10 quarters
|
|
3
Trevi Therapeutics
TRVI
$1.91B
| $41.2M | 7.61% |
2,210,852
+197,250
| +10% | +$2.87M |
2025 Q2
4 quarters
|
|
|
4
BrightSpring Health Services
BTSG
$11.7B
| $36.1M | 6.66% |
517,315
+463,515
| +862% | +$25.7M |
2025 Q3
3 quarters
|
|
|
5
Revolution Medicines
RVMD
$40.4B
| $34.7M | 6.41% |
185,390
+60,400
| +48% | +$8.82M |
2024 Q3
7 quarters
|
|
6
argenx
ARGX
$56.1B
| $27.6M | 5.09% |
29,739
| – | – |
2022 Q4
14 quarters
|
|
|
7
Alkermes
ALKS
$7.55B
| $23.5M | 4.34% |
+448,964
| New | +$17.5M |
2026 Q2
0 quarters
|
|
|
8
Travere Therapeutics
TVTX
$4.77B
| $19.3M | 3.55% |
339,033
+268,333
| +380% | +$11.9M |
2025 Q1
5 quarters
|
|
9
AstraZeneca
AZN
$265B
| $18.7M | 3.44% |
98,376
+3,000
| +3% | +$564K |
2022 Q4
14 quarters
|
|
10
NewAmsterdam Pharma
NAMS
$2.46B
| $17.1M | 3.15% |
503,936
| – | – |
2025 Q2
4 quarters
|
|
11
Dianthus Therapeutics
DNTH
$4.41B
| $15.9M | 2.93% |
162,990
| – | – |
2025 Q3
3 quarters
|
|
12
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.9B
| $15.8M | 2.92% |
+100,000
| New | +$13.5M |
2026 Q2
0 quarters
|
|
13
Quest Diagnostics
DGX
$27.3B
| $13.8M | 2.55% |
65,122
+24,305
| +60% | +$4.77M |
2025 Q1
5 quarters
|
|
14
Ionis Pharmaceuticals
IONS
$7.31B
| $11.4M | 2.11% |
144,376
| – | – |
2025 Q3
3 quarters
|
|
15
EyePoint Inc
EYPT
$33.7M
| $11M | 2.02% |
767,098
| – | – |
2023 Q4
10 quarters
|
|
16
Alumis Inc
ALMS
$879M
| $7.84M | 1.45% |
278,546
-46,500
| -14% | -$1.08M |
2026 Q1
1 quarter
|
|
17
Viking Therapeutics
VKTX
$3.19B
| $7.05M | 1.3% |
180,731
| – | – |
2022 Q4
14 quarters
|
|
|
18
Celcuity
CELC
$3.36B
| $6.21M | 1.15% |
59,316
+43,740
| +281% | +$5.05M |
2025 Q4
2 quarters
|
|
19
Cytokinetics
CYTK
$8.46B
| $6.02M | 1.11% |
70,700
+54,400
| +334% | +$3.91M |
2026 Q1
1 quarter
|
|
20
Merck
MRK
$348B
| $6M | 1.11% |
46,700
| – | – |
2026 Q1
1 quarter
|
|
21
Rapport Therapeutics
RAPP
$1.1B
| $5.77M | 1.07% |
138,508
| – | – |
2025 Q3
3 quarters
|
|
22
Johnson & Johnson
JNJ
$654B
| $5.74M | 1.06% |
22,600
| – | – |
2026 Q1
1 quarter
|
|
23
Guardant Health
GH
$24.8B
| $5.72M | 1.05% |
+38,100
| New | +$4.14M |
2026 Q2
0 quarters
|
|
24
Absci
ABSI
$1.98B
| $5.38M | 0.99% |
+464,444
| New | +$2.62M |
2026 Q2
0 quarters
|
|
25
Scholar Rock
SRRK
$5.29B
| $5.3M | 0.98% |
96,285
| – | – |
2025 Q1
5 quarters
|
|
Similar funds
WCM
CWWM
CAM
Artia Global Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Artia Global Partners held 57 positions worth $542M, up 8.5% from $499M the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Artia Global Partners deployed $30.9M of net new capital in Q2 2026, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Alkermes: 448,964 shares worth $23.5M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Abivax, an estimated $9.5M trimmed.
- Artia Global Partners's largest Q2 2026 buy was Alkermes: 448,964 shares worth $23.5M.
- Artia Global Partners added most to BrightSpring Health Services in Q2 2026, an estimated $25.7M increase.
- Artia Global Partners's biggest Q2 2026 reduction was Abivax, cutting an estimated $9.5M.
- Artia Global Partners fully exited Eli Lilly in Q2 2026, selling an estimated $35.2M.
- Artia Global Partners's ten largest holdings make up 65% of its $542M portfolio in Q2 2026.
- Artia Global Partners opened 7 new positions and closed 9 in Q2 2026.
- Artia Global Partners's portfolio value rose 8.5% quarter-over-quarter to $542M.
Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.